Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SoftReach

Financiado

Cerrado

Minimally-Invasive Soft-Robot-Assisted Deep-Brain Localized Therapeutics Deliver...

Minimally-Invasive Soft-Robot-Assisted Deep-Brain Localized Therapeutics Delivery for Neurological Disorders Robotics and imaging can revolutionize healthcare by overcoming limitations of existing practice and enabling the clinical translation of emerging treatments. Along this direction, SoftReach focuses on improving the treatment of n... ver más

31/01/2026

FOUNDATION FOR RES...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

IDRYMA TECHNOLOGIAS KAI EREVNAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-02-01

HORIZON-EIC-2022-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2022 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada hace 2 años

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

FOUNDATION FOR RESEARCH AND...

Lider

Proyectos interesantes

DBSBOT

Medical Technol...

Robotics and Au...

174K€ Cerrado

EDEN2020

Medical Technol...

Robotics and Au...

8M€ Cerrado

MAESTRO

Robotics and Au...

Medical Technol...

2M€ Cerrado

PTQ-10-03361

Robotics and Au...

Medical Technol...

21K€ Cerrado

PID2021-123657OB-C32

Robotics and Au...

Medical Technol...

141K€ Cerrado

DPI2016-80391-C3-3-R

Robotics and Au...

Medical Technol...

143K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 35 meses Fecha Inicio: 2023-02-01
Fecha Fin: 2026-01-31

Líder del proyecto

IDRYMA TECHNOLOGIAS KAI EREVNAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Robotics and imaging can revolutionize healthcare by overcoming limitations of existing practice and enabling the clinical translation of emerging treatments. Along this direction, SoftReach focuses on improving the treatment of neurological disorders (NDs), a major unmet healthcare challenge. Despite the devastating impact of NDs to millions, existing treatments have poor efficacy. SoftReach aims to radically improve treatments by providing localized delivery of therapeutics in deep-brain regions involved in ND pathophysiology. The proposed platform can enhance the efficacy of pharmaceutical treatments by bypassing limitations of systemic delivery, and provide means to implement promising cell therapies.Our paradigm-shifting ambition will be realised through two major innovations: 1) a submillimeter soft-growing steerable robotic platform, the first of its kind, which will utilize real-time MRI feedback to navigate through the spine subarachnoid space and the Ventricular System (VS), where it will attach μl-sized payloads (carriers of therapeutics) at specific locations. 2) Novel μl-sized tissue construct payloads (TCPs), built around precisely microfabricated deployable porous scaffolds so that they can attach stably on VS walls and deliver therapeutic factors to adjacent brain regions.The platform will be demonstrated via two parallel efforts. 1) The ability of the soft-growing robot to extend via the VS and safely deliver TCPs under real-time MRI feedback will be demonstrated in high-fidelity phantoms of the human VS. 2) TCP-mediated localised delivery of treatments (compounds, cells) via the VS will be demonstrated stereotactically in mice.By providing minimally-invasive access to deep-brain regions of major clinical importance that lie beyond the reach of existing procedures, SoftReach can revolutionize the clinical practice of ND treatments and provide disrupting tools that can impact multiple fields such as gene therapy, neurosurgery and oncology.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores